ArticleJournal of clinical microbiology2025
A universal point-of-care immunochromatographic test for the serodiagnosis of hepatitis D.
Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Novel Quantitative ELISA Demonstrates Lack of Correlation Between Serum HDV-RNA and Anti-HDV Antibody Levels in Chronic HDV Infection.Journal of viral hepatitis · 2026Article
- A comprehensive review of diagnostic approaches for hepatitis D.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hepatitis D is estimated to affect 12 million people worldwide and is caused by the hepatitis D virus (HDV), a defective virus that requires the presence of the hepatitis B virus (HBV) for infection. Here, we report a new recombinant antigen (DTH10.1) to detect anti-HDV IgG antibodies, designed to include a consensus sequence of the HDV antigen, based on bioinformatic analysis of the eight HDV genotypes. Using serum samples from patients living in the endemic area of the Brazilian Amazon basin, the enzyme-linked immunosorbent assay (ELISA) based on this protein displayed a sensitivity of 90.6% (95% CI: 84.2%-94.5%) and a specificity of 100% (95% CI: 94.2%-100.0%), while a rapid immunochromatographic test (ICT) showed a sensitivity of 91.3% (95% CI: 85.0%-95.1%) and specificity of 99.0% (95% CI: 94.5%-99.95%). Commercial monoclonal antibodies for HBV surface antigen (HBsAg) detection were then added to the test, resulting in a multiplex ICT with a sensitivity of 87.1% (95% CI: 81.3%-91.4%) for HBsAg and 95.2% (95% CI: 90.0%-97.8%) for anti-HDV IgG and specificity of 100% (95% CI: 91.0%-100.0%) and 98.0% (95% CI: 92.9%-99.6%), respectively. Finally, the three tests were evaluated against a panel of 79 patient samples infected, covering the eight HDV genotypes. The results indicated that all the DTH10.1-based tests were able to detect anti-IgG HDV antibodies with high sensitivity and specificity, regardless of the infecting HDV genotype. In conclusion, the prototypes developed for serodiagnosis of HDV using the DTH10.1 recombinant protein are promising tools for the universal diagnosis of HDV infection.IMPORTANCEThe manuscript outlines the complete strategy for developing tools for the diagnosis of hepatitis D, including an enzyme-linked immunosorbent assay (ELISA), an immunochromatographic test (ICT), and a multiplex ICT for the simultaneous detection of hepatitis B virus surface antigen and anti-hepatitis D virus (HDV) IgG antibodies. All the tests described are capable of detecting all eight HDV genotypes with high accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.